JPRN-jRCT1041230130招募中1 期
Study of metabolite changes by niacin-related supplements on healthy subjects - Niacin metabolism
Hirao Atsushi0 个研究点目标入组 20 人开始时间: 2024年1月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Healthy subjects
- •2) Young adults (18 to 29 years of age) and middle-aged and older adults (50 years of age or older)
- •(3) Individuals who have given their free and voluntary written consent to participate in the study after obtaining sufficient informed consent.
排除标准
- •(1) Pregnant, lactating, or possibly pregnant
- •(2) Those taking medicines or supplements containing nicotine, nicotinic acid, or NMN.
- •(3) Those with a history of hypersensitivity to medicines containing nicotine, nicotinic acid, or NMN, or to various foods containing nicotine, nicotinic acid, or NMN supplements.
- •(4) Those who are deemed inappropriate as research subjects by the Principal Investigator for other reasons.
研究者
相似试验
进行中（未招募）
不适用
Efficacy of niacin on phosphatic metabolism in patients with renal insufficiencyEUCTR2005-002221-31-DEClinic for Nephrology30
尚未招募
3 期
The effect of niacin on sodium, phosphorus, parathyroid hormone (PTH) and vitamin D levelsIRCT20190702044076N2Shahre-kord University of Medical Sciences60
已完成
2 期
A Comparative study on the effet of Niacin and Sevelamer on decreasing the phosphorous in dialysis patients referring to dialysis department of 5azar medical education center of gorgan in2019(1398)IRCT20190324043106N1Gorgan University of Medical Sciences76
已完成
不适用
Effect of NMN Supplementation on Organ System BiologyGlucose Metabolism DisordersNCT04571008Washington University School of Medicine56
进行中（未招募）
1 期
Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study) - NICOLaipoprotein (Lp)(a) has been associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral arterial vascular disease. Potential therapies to reduce elevated Lp(a) levels include nicotinic acid (niacin), but there is a lack of randomised controlled studies assessing the effectiveness of these therapies in lowering Lp(a) as a primary endpoint and in reducing cardiovascular events in the long term.EUCTR2006-005710-12-DECharité Universitätsmedizin Berlin150